Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis Gefurulimab—The First Effective Nanobody in Myasthenia Gravis Therapy
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from JAMA Network
JAMA Otolaryngology–Head & Neck Surgery : Newborn Hearing Screening in the Otoferlin Gene Therapy Era
JAMA Ophthalmology : Why Metrics Matter in Thyroid Eye Disease
JAMA Neurology : Smoking, Exhaled Carbon Monoxide, and Risk of Parkinson Disease
JAMA Psychiatry : GLP-1 Receptor Agonists, Mortality, and CV Outcomes in Mental Illness
Get summaries like this every morning.
Free AI-powered recaps of JAMA Network and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.